Sonlicromanol hydrochloride

• CAT Number: I045539
• CAS Number: 2162149-24-6
• Molecular Formula: C19H29ClN2O3
• Molecular Weight: 368.90
• Purity: ≥95%
• Synonyms: (2S)-6-hydroxy-2,5,7,8-tetramethyl-N-[(3R)-piperidin-3-yl]-3,4-dihydrochromene-2-carboxamide;hydrochloride
• InChI: InChI=1S/C19H28N2O3.ClH/c1-11-12(2)17-15(13(3)16(11)22)7-8-19(4,24-17)18(23)21-14-6-5-9-20-10-14;/h14,20,22H,5-10H2,1-4H3,(H,21,23);1H/t14-,19+;/m1./s1
• InChIKey: HVFWCHDZDIRYBZ-MQZJHDQISA-N
• SMILES: CC1=C(C2=C(CCC(O2)(C)C(=O)NC3CCCNC3)C(=C1O)C)C.Cl

Sonlicromanol hydrochloride (Cat No.: I045539) is a clinical-stage small-molecule drug candidate that targets redox modulation and mitochondrial function. It acts as a selective ROS–lipid peroxidation modulator with antioxidant and anti-inflammatory properties, aiming to restore cellular energy balance and reduce oxidative stress. Sonlicromanol has been investigated for treating mitochondrial disorders, neurodegenerative diseases, and inflammatory conditions, where impaired mitochondrial function plays a key role. The hydrochloride salt form improves solubility and pharmacological properties, making it suitable for therapeutic development and clinical research applications.

Reference

[1]. Ria de Haas, et al. Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease. Sci Rep. 2017 Sep 15;7(1):11733.
[Content Brief]